文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

使用EXENT®解决方案和液相色谱-质谱联用仪分析内源性单克隆免疫球蛋白。

Endogenous monoclonal immunoglobulins analyzed using the EXENT® solution and LC-MS.

作者信息

Barnidge David, Troske Derek, North Simon, Wallis Gregg, Perkins Mark, Harding Stephen

机构信息

The Binding Site, Part of ThermoFisher Scientific Research and Development Laboratory, 3777 40th Ave NW, Rochester, MN 55906, United States.

The Binding Site, Part of ThermoFisher Scientific, The Binding Site Group Ltd, 8 Calthorpe Road Edgbaston, Birmingham, UK.

出版信息

J Mass Spectrom Adv Clin Lab. 2024 Feb 16;32:31-40. doi: 10.1016/j.jmsacl.2024.02.002. eCollection 2024 Apr.


DOI:10.1016/j.jmsacl.2024.02.002
PMID:38405412
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10891330/
Abstract

INTRODUCTION: The EXENT® Solution, a fully automated system, is a recent advancement for identifying and quantifying monoclonal immunoglobulins in serum. It combines immunoprecipitation with MALDI-TOF mass spectrometry. Compared to gel-based methods, like SPEP and IFE, it has demonstrated the ability to detect monoclonal immunoglobulins in serum at lower levels. In this study, samples that tested negative using EXENT® were reflexed to LC-MS to determine if the more sensitive LC-MS method could identify monoclonal immunoglobulins missed by EXENT®. OBJECTIVES: To assess whether monoclonal immunoglobulins that are not detected by EXENT® can be detected by LC-MS using a low flow LC system coupled to a Q-TOF mass spectrometer. METHODS: Samples obtained from patients confirmed to have multiple myeloma (MM) were diluted with pooled polyclonal human serum and analyzed using EXENT®. If a specific monoclonal immunoglobulin was not detected by EXENT®, the sample was then subjected to analysis by LC-MS. For the LC-MS analysis, the sample eluate, obtained after the MALDI-TOF MS spotting step, was collected and transferred to an autosampler tray for subsequent analysis using LC-MS. CONCLUSION: LC-MS has the capability to detect monoclonal immunoglobulins that are no longer detected by EXENT®. Reflexing samples to LC-MS for analysis does not involve additional sample handling, allowing for a faster time-to-result compared to current approaches, such as Next-Generation Sequencing, Next-Generation Flow, and clonotypic peptide methods. Notably, LC-MS offers equivalent sensitivity in detecting these specific monoclonal immunoglobulins.

摘要

引言:EXENT® 解决方案是一种全自动系统,是血清中鉴定和定量单克隆免疫球蛋白的最新进展。它将免疫沉淀与基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)相结合。与基于凝胶的方法(如血清蛋白电泳(SPEP)和免疫固定电泳(IFE))相比,它已证明能够检测血清中较低水平的单克隆免疫球蛋白。在本研究中,使用EXENT®检测呈阴性的样本被送去进行液相色谱 - 质谱联用(LC-MS)分析,以确定更灵敏的LC-MS方法是否能识别出EXENT®遗漏的单克隆免疫球蛋白。 目的:评估使用与四极杆飞行时间质谱仪(Q-TOF)联用的低流速液相色谱系统,LC-MS能否检测出EXENT®未检测到的单克隆免疫球蛋白。 方法:从确诊为多发性骨髓瘤(MM)的患者中获取样本,用混合的多克隆人血清稀释后使用EXENT®进行分析。如果EXENT®未检测到特定的单克隆免疫球蛋白,则对该样本进行LC-MS分析。对于LC-MS分析,在MALDI-TOF MS点样步骤后获得的样品洗脱液被收集并转移至自动进样器托盘,以便随后使用LC-MS进行分析。 结论:LC-MS有能力检测出EXENT®不再能检测到的单克隆免疫球蛋白。将样本送去进行LC-MS分析无需额外的样本处理,与当前方法(如下一代测序、下一代流式细胞术和克隆型肽方法)相比,能更快得到结果。值得注意的是,LC-MS在检测这些特定单克隆免疫球蛋白时具有同等的灵敏度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10891330/c133af5cf4e7/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10891330/980e4195aca4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10891330/d5944fc737a2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10891330/16a570551865/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10891330/8136ef0cc0d8/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10891330/c133af5cf4e7/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10891330/980e4195aca4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10891330/d5944fc737a2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10891330/16a570551865/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10891330/8136ef0cc0d8/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10891330/c133af5cf4e7/gr5.jpg

相似文献

[1]
Endogenous monoclonal immunoglobulins analyzed using the EXENT® solution and LC-MS.

J Mass Spectrom Adv Clin Lab. 2024-2-16

[2]
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.

Blood Adv. 2022-6-14

[3]
Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry.

Clin Chem. 2019-6-6

[4]
Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS.

J Proteome Res. 2014-4-4

[5]
Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.

Clin Chim Acta. 2021-5

[6]
Detection of serum M-protein in acetonitrile precipitates by MALDI-TOF mass spectrometry: A novel, low-cost methodology.

Ann Clin Biochem. 2023-9

[7]
Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy.

J Proteome Res. 2014-2-11

[8]
MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.

Clin Chim Acta. 2019-2-18

[9]
A new strategy for faster urinary biomarkers identification by Nano-LC-MALDI-TOF/TOF mass spectrometry.

BMC Genomics. 2008-11-14

[10]
Detecting monoclonal immunoglobulins in human serum using mass spectrometry.

Methods. 2015-6-15

引用本文的文献

[1]
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy.

Drugs. 2025-9-4

[2]
Mass Spectrometry-Based Proteomics in Clinical Diagnosis of Amyloidosis and Multiple Myeloma: A Review (2012-2024).

J Mass Spectrom. 2025-3

[3]
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.

Blood Cancer J. 2024-5-29

[4]
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.

Blood. 2024-8-29

本文引用的文献

[1]
Added Value of Internal Fragments for Top-Down Mass Spectrometry of Intact Monoclonal Antibodies and Antibody-Drug Conjugates.

Anal Chem. 2023-6-20

[2]
Advances in minimal residual disease monitoring in multiple myeloma.

Crit Rev Clin Lab Sci. 2023-11

[3]
A multiparameter optimization in middle-down analysis of monoclonal antibodies by LC-MS/MS.

J Mass Spectrom. 2023-3

[4]
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.

Lancet Haematol. 2022-5

[5]
Approaches to Heterogeneity in Native Mass Spectrometry.

Chem Rev. 2022-4-27

[6]
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.

Blood Cancer J. 2021-2-5

[7]
Development of novel methods for non-canonical myeloma protein analysis with an innovative adaptation of immunofixation electrophoresis, native top-down mass spectrometry, and middle-down sequencing.

Clin Chem Lab Med. 2021-3-26

[8]
A Universal Score for Deconvolution of Intact Protein and Native Electrospray Mass Spectra.

Anal Chem. 2020-3-17

[9]
Cyclization of N-Terminal Glutamic Acid to pyro-Glutamic Acid Impacts Monoclonal Antibody Charge Heterogeneity Despite Its Appearance as a Neutral Transformation.

J Pharm Sci. 2019-5-27

[10]
The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic.

Am J Hematol. 2017-6-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索